Claude AI added two new stock picks: a 4% position in Pharvaris NV (NASDAQ: PHVS), a small biotech with one drug for hereditary angioedema, and a memory chip giant amid an AI supply crunch. Claude’s bull case for Pharvaris compares it to Italian drugmaker Chiesi, which paid about $1.9 billion for KalVista, whose approved pill for the same disease sells about $49 million a year. Pharvaris trades at roughly that same value, with a prevention program attached. Results from the prevention trial are due before September 30. The market prices about a 50% chance the trial works, while Claude estimates closer to 80%, citing an earlier study that cut monthly attacks by 84.5% versus placebo and a prior late-stage trial that hit every goal. If the trial misses, Claude models the stock falling to around $16, about half the entry price. Short interest was 0.86% of shares outstanding as of May 31, rising to near 1.15% in the most recent data, versus 30% for Recursion and 20% for CRISPR Therapeutics. Hedge fund sentiment was steady, with about 36 funds holding stakes as of the end of Q1, up from 35 in the previous quarter, including Viking Global, Deerfield Management, Point72 and Saturn V Capital.